Skip to main content

Read more about our corporate brand here.

Search
Search
Reports

Healthcare Industry Trends

2024 Annual Report
Raysa Bousleiman, Tim Lew, Alex Lennox-Miller, Anjalika Komatireddy, Jackie Spencer, Timot Lamarre

Key takeaways

Our Healthcare Investments and Exits report shows a surge in biotech AI investment, strong early-stage momentum and mixed signals from valuation trends.

$5.6B

Invested in biotech AI in 2024

Driven largely by mega-deals, investment in biotech AI nearly tripled.

Nearly 40%

Of all healthcare deals with a declared Series went to seed-stage companies

Seed and Series A rounds claimed a majority of healthcare deals in 2024.

1

Number of healthcare subsectors experiencing a drop in down and flat rounds

Market corrections may be starting to wind down in biotech, devices and diagnostics/tools.

The data

2024 was a banner year for biotech, with significant investments in AI-powered drug discovery and protein engineering and fewer down and flat rounds. Though M&A activity is muted, the IPO market is promising. A handful of companies have already filed for IPOs in 2025, and decent performances from companies that debuted in 2024 should build confidence.

INVESTMENTS IN AI

Biotech AI investment outpaces 2021

With protein discovery and structure platforms leading the space, biotech AI was one of the very few tech groups that surpassed their 2021 investment levels.

The biggest impacts of AI are still emerging and most clinical trials take at least five years, so VCs are investing now with an eye toward putting themselves on the cutting edge later this decade.

Infographic depicting US and Europe biopharma therapeutics and research AI investment from 2019 to 2024 Note: Deals $100M and above are considered mega-deals. All 2024 data is as of 11/30/2024. Source: PitchBook Data, Inc., and SVB proprietary data and analysis
Infographic depicting US healthcare seed share surges by series and seed share of deals Note: Analysis includes only rounds with a declared Series round. Source: PitchBook Data, Inc., and SVB proprietary data and analysis
DEAL COUNT

Early-stage rounds are taking off

A majority of deals with a declared Series in 2024 went to Series A and seed-stage companies, with seed rounds alone accounting for nearly 40% of total deals.

This early-stage momentum was most significant in healthtech, where seed deals outnumbered Series A deals two to one.

VALUATIONS

Down rounds have begun to level off

Down and flat rounds have decreased for biopharma, and levelled off in other sectors for the first time in four years.

However, the number of undisclosed rounds has increased, suggesting market valuations may still be resetting.

Infographic depicting healthcare valuation changes for Series A and beyond for US deals Note: Up rounds are defined as deals where the pre-money valuation is higher than the prior deal’s post-money valuation. Only deals with a reported deal size are considered for this analysis. Total rows and columns may not add up due to rounding or companies in stealth. Source: PitchBook Data, Inc., and SVB proprietary data and analysis

First Citizens Innovation Banking's Life Science and Healthcare Practice

Discover how First Citizens Innovation Banking supports healthcare innovators and investors.

More about the authors

Raysa Bousleiman

Raysa Bousleiman

Tim Lew

Tim Lew

Director of Business Development

Alex Lennox-Miller
Market Insights

Alex Lennox-Miller

Senior Researcher

Anjalika Komatireddy

Anjalika Komatireddy

Jackie Spencer

Jackie Spencer

Timot Lamarre

Timot Lamarre


Explore other First Citizens Innovation Banking Reports

The Future of Healthtech 2026 Reports
Read Report Report

The Future of Healthtech 2026

Nov 09, 2026

Megan Scheffel, Adam Tweedy, Dennis He, Matt Donne, Alex Lennox-Miller, Urbashee Paul, Josh Pherigo

The Future of Fintech 2026 Reports
Read Report Report

The Future of Fintech 2026

Oct 13, 2026

Nick Christian, Brian Foley, Julie Wagne, Sophie McNaught, Josh Pherigo, Eli Oftedal, Andrew Pardo

The Future of Climate Tech Reports
Read Report Report

The Future of Climate Tech

Apr 15, 2026

Jordan Kanis, Eli Oftedal, Josh Pherigo, Andrew Pardo


The views expressed in this report are solely those of the authors and do not necessarily reflect the views of First Citizens Innovation Banking or Counterpart.

First-Citizens Bank & Trust Company is not licensed to undertake banking business in any country outside the United States or to undertake any other regulated activity in any country outside the United States.

All non-SVB named companies listed throughout this document are independent third parties and are not affiliated with Silicon Valley Bank, a division of First-Citizens Bank & Trust Company.

This material, including without limitation to the statistical information herein, is provided for informational purposes only. The material is based in part on information from third-party sources that we believe to be reliable, but which has not been independently verified by us, and, as such, we do not represent the information is accurate or complete. The information should not be viewed as tax, accounting, investment, legal or other advice, nor is it to be relied on in making an investment or other decision. You should obtain relevant and specific professional advice before making any investment decision. Nothing relating to the material should be construed as a solicitation, offer or recommendation to acquire or dispose of any investment, or to engage in any other transaction.

Back to top
You are now leaving First Citizens Innovation Banking

You will be directed to a different website or mobile app that has its own terms of use, visitor agreement, security and privacy policies. First Citizens Innovation Banking is not responsible for (and does not provide) any products, services or content at the third party site or app, except for the products and services that carry the First Citizens Innovation Banking name.